4 patents
Utility
Multivalent Chlorotoxin Chimeric Antigen Receptors
18 Aug 22
Described are γδ T-cells that express a multivalent CLTX-CAR and also express a survival factor, a population of the γδ T-cells that express a multivalent CLTX-CAR and the survival factor, pharmaceutical compositions thereof, and methods of treating cancer or a tumor in a subject comprising administering to a subject an effective amount of the multivalent CLTX-CAR γδ T-cells and co-administering a chemotherapeutic agent, e.g., the chemotherapeutic agent to which the survival factor confers resistance.
Lei Ding, Lawrence S. Lamb, JR.
Filed: 20 Jan 22
Utility
Compositions and Methods for Treating Cancer
21 Oct 21
The invention provides combination therapies for treating cancer comprising compositions and methods for γδ T cell immunotherapy in combination DDR inhibitors, including but not limited to PARP inhibitors.
Lawrence S. Lamb, JR., William Ho
Filed: 4 May 21
Utility
Compositions and Methods for Cancer Immunotherapy
17 Jun 20
The present invention provides compositions and methods for combination therapy comprising administering to a patient in need thereof, drug-resistant immunotherapy, immune checkpoint inhibitors, and chemotherapy for the treatment of cancer.
William Ho, JR., Lawrence S. Lamb, JR.
Filed: 15 Dec 19
Utility
Compositions and Methods for Cancer Immunotherapy
18 Dec 19
The present invention provides compositions and methods for combination therapy comprising administering to a patient in need thereof, drug-resistant immunotherapy, immune checkpoint inhibitors, and chemotherapy for the treatment of cancer.
Steven A. Lisi, William Ho, Lawrence S. Lamb, JR.
Filed: 17 Feb 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first